Alto Neuroscience, Inc. (ANRO)
- Previous Close
14.13 - Open
13.94 - Bid 13.30 x 1100
- Ask 15.91 x 1100
- Day's Range
13.96 - 14.18 - 52 Week Range
12.78 - 24.00 - Volume
22,746 - Avg. Volume
267,118 - Market Cap (intraday)
381.215M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.33
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
www.altoneuroscience.comRecent News: ANRO
Compare To: ANRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANRO
Valuation Measures
Market Cap
381.21M
Enterprise Value
308.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-8.93
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.38%
Return on Equity (ttm)
-67.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.3M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
82.55M
Total Debt/Equity (mrq)
14.03%
Levered Free Cash Flow (ttm)
-23.45M